Refine by
Liver Cell Articles & Analysis
22 news found
Obesity is a metabolic condition resulting from an imbalance between the energy consumed and the energy expended. This is often caused by an increase in the intake of calorie-dense foods and a decrease in physical activity, leading to an abnormal build-up of fat. Such fat accumulation can have serious health consequences, raising the risk of chronic diseases like cardiovascular conditions, ...
P000912-LYSK1-A.0 Soft tissue homogenizing CK14 The CK14 kit is the perfect solution for soft tissue homogenization, like brain, liver, kidney, skin, plant leaves, mammalian cells and more. Compatible with Precellys Evolution Touch, Precellys 24 Touch and Minilys, the kit comes in different sizes, including 0.5mL, 2mL, 2mL Protein Safe or 7mL standard tubes. ...
This collaboration could extend the reach of gene editing for liver and lung disease targets. “AskBio’s pioneering gene editing technology is a powerful complement to our modular SORT LNP genetic medicines platform, which enables the precise delivery of a wide variety of genetic cargoes to specific organs and cells, including large, complex genetic ...
ByBayer AG
Target knockdown and safety results support continued clinical development Alnylam and Regeneron intend to initiate a Phase 2 study in late 2022 Detailed results to be presented at an upcoming medical congress CAMBRIDGE, Mass. & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Sep. 15, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals (Nasdaq: REGN) announced today ...
Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer. ...
ByxCures
By acquiring Cognate BioServices, Cobra Biologics, and Vigene Biosciences, its CDMO platforms now cover cell therapy, viral vectors, and small circular DNA molecule production. ...
ASC618 is designed to deliver a shortened, but optimized version of the gene to liver cells. ASC Therapeutics has received IND clearance, as well as key regulatory designations in the U.S. and Europe for its ASC618 program. ...
ASC618 is designed to deliver a shortened, but optimized version of the gene to liver cells, which is expected to work better than the full version. ...
ASC618 has the potential to increase durability of clotting factor biosynthesis and secretion by minimizing cellular stress and induction of the unfolded protein response, which may lead to diminished FVIII production from liver cells. ASC Therapeutics will conduct a phase 1/2 clinical trial to evaluate the safety, tolerability, and preliminary efficacy of ...
The collaboration between Novo Nordisk and Dicerna encompassed the exploration of more than 30 liver cell targets with the potential to deliver multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases. ...
” HemoShear’s REVEAL-Tx™ platform has been utilized to create a model of NASH that recapitulates hallmark features of liver fat build up, increased cell stress and inflammation, and extracellular matrix signaling that was published in the Journal of Clinical Investigation Insight. In addition, Nature Scientific Reports published the ...
He has over 12 years of industry experience, including leading the R&D group for hepatic biology and advanced culture models in the Division of Cell Biology at Thermo Fisher Scientific/Life Technologies, and most recently, leading process development activities for cell-based therapies for liver disease as Director of Cell ...
Electrically charged proteins within the cell are critical for cell division, making the rapidly dividing cancer cells vulnerable to electrical interference. ...
HemoShear scientists created in vitro models of MMA and PA to accurately reflect these human disease states by applying principles of physiological blood flow to human tissue from the livers of MMA and PA patients who underwent transplant. Administration of HST5040 to the patients’ liver cells led to dose-dependent reductions to normal or ...
Central to the innovation is a biological scaffold, adapted from pig lung tissue, that holds beta cells. Those cells release insulin based on the patient’s blood sugar levels. ...
Servier, an independent international pharmaceutical company, and Poietis, a leader in the production of living bioprinted tissues, have announced a scientific partnership to use Poietis’s 4D bioprinting technology for the development and production of liver tissues. This partnership seeks to improve the detection of drug-induced liver lesions as ...
ByPoietis
Hepatitis C (HCV) infection is the most common cause of liver cell carcinoma and liver transplants in Europe, which are possible late–stage effects of a chronic infection, alongside cirrhosis of the liver. ...
When healthy liver cells are depleted by long-term exposure to toxic chemicals, the newly discovered cells, known as hybrid hepatocytes, generate new tissue more efficiently than normal liver cells. Importantly, they divide and grow without causing cancer, which tends to be a risk with rapid cell ...
Adult stem cells are undifferentiated cells, found throughout the body after embryonic development, which multiply by cell division to replenish dying cells and regenerate damaged tissue. ...
Data from a new study shows that triclosan causes liver fibrosis and cancer in laboratory mice through molecular mechanisms that are also relevant for humans. ...